In general, metabolic disorders lead to abnormal accumulation or lack of metabolic substances in the body - such metabolic diseases have serious impacts on human health. Metabolic syndrome is characterized by a combination of obesity accompanied with other metabolic abnormalities, such as hypertriglyceridemia, decreased HDL levels, elevated blood pressure, and elevated fasting blood glucose levels. Obesity is increasing worldwide, and its association with these metabolic symptoms increases the risk of diabetes, cardiovascular disease, and stroke.
Metabolic disease models often use specific rodent models, which aim to mimic metabolic disease changes in human body to evaluate the pathophysiology of metabolic diseases.
Metabolic disease models which closely replicate the metabolic disease state in humans are an ideal tool for drug development, providing valuable insights into disease mechanisms, validation of novel therapeutic targets, as well as testing the safety and efficacy of drugs.
Animal models of metabolic diseases are important tools for revealing pathophysiology and providing novel insights for the development of new therapies and drugs. So far, many animal models have been developed and studied, using one or more of the following research model generation methods: genetic engineering, diet-induced, and chemically induced. These methods reflect how metabolic syndrome is a result of the combined effects if genes, diet, and environment. Metabolic disease models are used to monitor the molecular mechanisms and functional changes related to metabolic diseases.
Typical Metabolic Diseases Models:
Cyagen had developed a series of metabolic disease models, such as obesity, diabetes, atherosclerosis, non-alcoholic fatty liver disease, pancreatitis, etc. In addition to genetically engineered mouse models, some models simulate human diseases through drug induction and/or diet induction techniques. Researchers may use such models to study the pathogenesis of related diseases, as well as perform drug screening and efficacy evaluations.
|Metabolic Disease Models||Model Type|
|Obesity Mouse Models||Diet-induced obesity (DIO) Model|
|Diabetes Mellitus (DM) Mouse Models||Type 2 Diabetes Mellitus (T2DM) Mouse Model|
|Type 1 Diabetes Mellitus (T1DM) Mouse Model|
|Non-alcoholic Fatty Liver Disease (NAFLD) Mouse Models||Diet-induced Non-alcoholic Fatty Liver Disease (NAFLD) Mouse Model|
|Chemically Induced Non-alcoholic Fatty Liver Disease (NAFLD) Mouse Model|
|Non-alcoholic Fatty Liver Disease (NAFLD) Mouse Model (Gene-editing)|
|Composite (combined) Model - Non-alcoholic Fatty Liver Disease (NAFLD) Model|
|Atherosclerosis Mouse Model||Composite (combined) Model - Atherosclerosis Mouse Model|
|Atherosclerosis Mouse Model (Gene-editing)|
|Pancreatitis Mouse Models||Acute Pancreatitis Mouse Model|
|Chronic Pancreatitis Mouse Model|
Cyagen can provide you with a variety of metabolic disease models along with phenotype analysis services – delivering reliable and expedient data reporting for your project.